Companies / GI Windows Surgical

Medical device company profile

GI Windows Surgical

Massachusetts medical device manufacturer developing and commercializing Flexagon magnetic anastomosis technology for gastrointestinal surgery.

Medical Device ManufacturerGastroenterology & Digestive HealthSurgery & Procedural CareGastroenterologySurgical Instruments

Headquarters🇺🇸Canton, Massachusetts, United States

Founded2012

Commercial statusCommercially availableCommercial-stage Flexagon Plus OTOLoc platform; availability and indications depend on configuration.

Employees11–50 ^[11]LinkedIn company-size range · Checked 2026-11-01

Estimated revenueNot confirmed

Disclosed fundingUS$37 million ^[7]Additional financing announced November 15, 2024. Individual financing round, not cumulative capital raised.

Official websitewww.giwindows.com ↗

Company overview

GI Windows Surgical is a Massachusetts medical device company founded in 2012 and led by president and CEO Brian Tinkham. Its October 2026 announcement identifies Canton as its base. The company develops magnetic compression systems for creating surgical connections between parts of the gastrointestinal tract.

Its Flexagon platform uses self-forming magnets with laparoscopic and endoscopic delivery tools. The Flexagon Plus OTOLoc system combines magnetic tissue compression with an access component designed to establish an immediate opening while surrounding tissue heals.

The company has FDA-cleared configurations and describes itself as commercial-stage. In October 2026, it announced an expanded gastric indication. A US$37 million Series B financing announced in November 2024 supported clinical development and commercialization.

^{[5][6][7][9][11]}

Leadership

5 people

Brian TinkhamPresident & Chief Executive Officer ^[9]

Peter LukinChief Operating Officer ^[9]

Gerry SheridanChief Financial Officer ^[9]

Erik B. Wilson, MDChief Medical Officer ^[9]

Yverre BobayVice President of Regulatory Affairs ^[9]

Products & regulatory status How does MedTechIndex get this information?

Summary

FDA records document four 510(k) clearances across Flexagon and Flexagon Plus OTOLoc configurations from January 2025 through January 2026. K253550 covers side-to-side jejunum-to-jejunum and ileum-to-ileum anastomoses in adults older than 21; its labeling states that effects on weight loss were not studied. ^[1][2][3][4]

On October 29, 2026, GI Windows announced an expanded gastric indication for Flexagon Plus OTOLoc, including stomach-to-small-intestine connections. This company-reported expansion is distinct from the indications in the January 2026 FDA record. ^[5][4]

Regulatory snapshot How to read this snapshot

U.S. FDA

4+
510(k) clearances: —
De Novo grants: —
PMA approvals: —
Recall events

Latest recorded source review: 2026-11-01.

Commercial portfolio snapshot

Documented commercial product families.

Gastrointestinal anastomosis system

Flexagon magnetic anastomosis platform with OTOLoc ↗

Self-forming magnets and delivery instruments used to create connections between gastrointestinal segments. Opposing magnets compress tissue to support anastomotic healing; the Flexagon Plus OTOLoc configuration incorporates an access component to create an immediate lumen. Laparoscopic and endoscopic delivery configurations are documented, with indications specific to each cleared system. ^{[3][4][1][2][6][8][5]}

Commercial platform · FDA-cleared configurations